Investors
Our business model allows for revenues arising from product sales to be invested development operations, where new medicines can be produced for the benefit of more and more patients in future.
| INSTITUTIONAL INVESTORS | Leading Institutional investors in ProStrakan |
|---|---|
| Warburg Pincus (through various entities) | 24.49% |
| Aventis Pharma SA | 12.68% |
| Aberforth Partners | 10.66% |
|
LMS Capital |
8.75% |
| Schroders plc |
5.07% |
Directors, employees and non-institutional shareholders hold 15% of the company.
For the latest ProStrakan share price information, graphs and reports click here
ProStrakan markets a range of products in a number of key EU territories. To find out more click here
For our latest published financial results or historical information, please click here
